Icos Pafase Phase III Sepsis Trial Will Collect Cost-Effectiveness Data
Executive Summary
Icos will collect cost-effectiveness data in the Phase III trial for its sepsis treatment Pafase (recombinant platelet activating factor acetylhydrolase).
You may also be interested in...
Icos Pafase for sepsis discontinued
Icos discontinues severe sepsis agent Pafase after Phase III study failed to meet primary efficacy endpoint of 28-day all-cause mortality. Icos commenced COMPASS trial in April 2001; the study had enrolled 1,250 patients of 2,500 planned. Icos hoped to gain approval for Pafase (recombinant human platelet-activating factor acetylhydrolase) based on the single study (1"The Pink Sheet" Aug. 27, 2001, p. 25). Icos has a second compound, IC14, in Phase II for community acquired pneumonia-related sepsis...
Icos Pafase for sepsis discontinued
Icos discontinues severe sepsis agent Pafase after Phase III study failed to meet primary efficacy endpoint of 28-day all-cause mortality. Icos commenced COMPASS trial in April 2001; the study had enrolled 1,250 patients of 2,500 planned. Icos hoped to gain approval for Pafase (recombinant human platelet-activating factor acetylhydrolase) based on the single study (1"The Pink Sheet" Aug. 27, 2001, p. 25). Icos has a second compound, IC14, in Phase II for community acquired pneumonia-related sepsis...
Lilly Xigris Action Date Is Oct. 27; FDA Preparing For Advisory Cmte. Review
The FDA user fee action date for Lilly's sepsis therapy Xigris (formerly Zovant) is extended until Oct. 27.